These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

808 related articles for article (PubMed ID: 18799360)

  • 1. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
    Jones J; Loftus EV; Panaccione R; Chen LS; Peterson S; McConnell J; Baudhuin L; Hanson K; Feagan BG; Harmsen SW; Zinsmeister AR; Helou E; Sandborn WJ
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1218-24. PubMed ID: 18799360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
    Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings.
    Sipponen T; Kärkkäinen P; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1221-9. PubMed ID: 18752630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease.
    Scarpa M; D'Incà R; Basso D; Ruffolo C; Polese L; Bertin E; Luise A; Frego M; Plebani M; Sturniolo GC; D'Amico DF; Angriman I
    Dis Colon Rectum; 2007 Jun; 50(6):861-9. PubMed ID: 17473939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.
    Sipponen T; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Inflamm Bowel Dis; 2008 Jan; 14(1):40-6. PubMed ID: 18022866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment.
    Sipponen T; Björkesten CG; Färkkilä M; Nuutinen H; Savilahti E; Kolho KL
    Scand J Gastroenterol; 2010 Mar; 45(3):325-31. PubMed ID: 20034360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity.
    Schaffer T; Schoepfer AM; Seibold F;
    J Crohns Colitis; 2014 Sep; 8(9):1125-32. PubMed ID: 24636141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of disease location on fecal calprotectin levels in Crohn's disease.
    Gecse KB; Brandse JF; van Wilpe S; Löwenberg M; Ponsioen C; van den Brink G; D'Haens G
    Scand J Gastroenterol; 2015 Jul; 50(7):841-7. PubMed ID: 25636819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal calprotectin in the assessment of Crohn's disease activity.
    Gaya DR; Lyon TD; Duncan A; Neilly JB; Han S; Howell J; Liddell C; Stanley AJ; Morris AJ; Mackenzie JF
    QJM; 2005 Jun; 98(6):435-41. PubMed ID: 15879440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity.
    Klimczak K; Lykowska-Szuber L; Eder P; Krela-Kazmierczak I; Stawczyk-Eder K; Szymczak A; Michalak M; Studniarek A; Linke K
    Eur J Intern Med; 2015 Oct; 26(8):623-7. PubMed ID: 26198785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease.
    Sipponen T; Savilahti E; Kärkkäinen P; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Inflamm Bowel Dis; 2008 Oct; 14(10):1392-8. PubMed ID: 18484671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
    Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH;
    Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selected biologic markers of inflammation and activity of Crohn's disease.
    Karczewski J; Swora-Cwynar E; Rzymski P; Poniedziałek B; Adamski Z
    Autoimmunity; 2015; 48(5):318-27. PubMed ID: 25707687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
    Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis.
    Masoodi I; Kochhar R; Dutta U; Vaishnavi C; Prasad KK; Vaiphei K; Kaur S; Singh K
    J Gastroenterol Hepatol; 2009 Nov; 24(11):1768-74. PubMed ID: 20136960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the response of patients with Crohn's disease to biological therapy using new non-invasive markers: lactoferrin and calprotectin.
    Nogueira IM; Miszputen SJ; Ambrogini O; Artigiani-Neto R; Carvente CT; Zanon MI
    Arq Gastroenterol; 2013 Apr; 50(2):130-7. PubMed ID: 23903623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.
    Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Leach S; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Day AS; Desmond PV; Gearry RB
    Gastroenterology; 2015 May; 148(5):938-947.e1. PubMed ID: 25620670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.
    Lobatón T; López-García A; Rodríguez-Moranta F; Ruiz A; Rodríguez L; Guardiola J
    J Crohns Colitis; 2013 Dec; 7(12):e641-51. PubMed ID: 23810085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.